Medical Care

Until recently, the HACEK bacteria were uniformly susceptible to ampicillin. Recently, however, beta-lactamase–producing strains of HACEK have been identified.

A third-generation cephalosporin (ceftriaxone or cefotaxime) should be considered the drug of choice for HACEK endocarditis.

Ampicillin plus an aminoglycoside can be used for susceptible isolates.

In patients unable to take beta-lactams, options include trimethoprim-sulfamethoxazole, fluoroquinolones, or aztreonam.

Native valve endocarditis should be treated for 3-4 weeks. Prosthetic valve endocarditis requires 6 weeks of treatment.

The American Heart Association recommends treatment with ceftriaxone, ampicillin-sulbactam, or ciprofloxacin for 4 weeks.

Prevention

Antibiotic prophylaxis given prior to dental procedures is primarily directed at Streptococcus viridans but should also help prevent infection due to HACEK bacteria.^[14]

Further Outpatient Care

Patients with C hominis endocarditis can be treated in an outpatient setting but should remain on intravenous antimicrobial therapy for the duration of treatment.

Risks of embolic complications may arise during therapy.

Patients should be continuously and carefully monitored and should have prompt access to medical care, including cardiac surgery, in the event of complications.

Further Inpatient Care

Native valve endocarditis should be treated for 4 weeks. Prosthetic valve endocarditis requires 6 weeks of treatment.

Medication

Choudhury S, Isais FS, Lee CC. Nonsurgical management of mitral valve endocarditis due to Cardiobacterium valvarum in a patient with a ventricular septal defect. J Clin Microbiol. 2013 Jun. 51 (6):1996-7. [QxMD MEDLINE Link].
Ambrosioni J, Martinez-Garcia C, Llopis J, Garcia-de-la-Maria C, Hernández-Meneses M, Tellez A, et al. HACEK infective endocarditis: Epidemiology, clinical features, and outcome: A case-control study. Int J Infect Dis. 2018 Nov. 76:120-125. [QxMD MEDLINE Link]. [Full Text].
Bonavent TB, Nielsen XC, Kristensen KS, Ihlemann N, Moser C, Christensen JJ. Cardiobacterium hominis and Cardiobacterium valvarum: Two Case Stories with Infective Episodes in Pacemaker Treated Patients. Open Microbiol J. 2016. 10:183-187. [QxMD MEDLINE Link]. [Full Text].
Okumura E, Tsurukiri J, Yamanaka H, Nakagawa Y, Ootsuka K, Tanaka Y. Intracranial Hemorrhaging following Cardiobacterium hominis Endocarditis. Intern Med. 2019 Jan 10. [QxMD MEDLINE Link].
Hagiya H, Kokeguchi S, Ogawa H, Terasaka T, Kimura K, Waseda K, et al. Aortic vascular graft infection caused by Cardiobacterium valvarum: a case report. J Infect Chemother. 2014 Dec. 20 (12):804-9. [QxMD MEDLINE Link].
Ducoulombier V, Budzik JF, Dehecq E, Baclet N, Houvenagel E. [Cardiobacterium hominis septic arthritis]. Med Mal Infect. 2014 Mar. 44 (3):129-31. [QxMD MEDLINE Link].
Manderwad GP, Kodiganti M, Ali MJ. Cardiobacterium hominis-induced acute dacryocystitis and lacrimal abscess. Indian J Ophthalmol. 2014 Apr. 62 (4):495-7. [QxMD MEDLINE Link].
Vidal-Lampurdanes C, Dueñas J, Hervás D, Reina C, Gil J, Hervás JA. Cardiobacterium hominis is a rare cause of neonatal sepsis. Pediatr Infect Dis J. 2012 May. 31 (5):541-2. [QxMD MEDLINE Link].
Wong D, Carson J, Johnson A. Subacute bacterial endocarditis caused by Cardiobacterium hominis: A case report. Can J Infect Dis Med Microbiol. 2015 Jan-Feb. 26 (1):41-3. [QxMD MEDLINE Link].
Fukuchi T, Iwata K, Ohji G. Failure of early diagnosis of infective endocarditis in Japan--a retrospective descriptive analysis. Medicine (Baltimore). 2014 Dec. 93 (27):e237. [QxMD MEDLINE Link].
Wormser GP, Bottone EJ. Cardiobacterium hominis: review of microbiologic and clinical features. Rev Infect Dis. Jul-Aug 1983. 5(4):680-91. [QxMD MEDLINE Link].
Yen RF, Chen YC, Wu YW, Pan MH, Chang SC. Using 18-fluoro-2-deoxyglucose positron emission tomography in detecting infectious endocarditis/endoarteritis: a preliminary report. Acad Radiol. 2004 Mar. 11(3):316-21. [QxMD MEDLINE Link].
El Hajjaji I, Mansencal N, Dubourg O. Diagnosis of Cardiobacterium hominis endocarditis: usefulness of positron emission tomography. Int J Cardiol. 2012 Sep 20. 160(1):e3-4. [QxMD MEDLINE Link].
Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007 Apr 19. [QxMD MEDLINE Link].
Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005 Jun 14. 111(23):e394-434. [QxMD MEDLINE Link].
Berbari EF, Cockerill FR 3rd, Steckelberg JM. Infective endocarditis due to unusual or fastidious microorganisms. Mayo Clin Proc. 1997 Jun. 72(6):532-42. [QxMD MEDLINE Link].
Elliott TS, Foweraker J, Gould FK, Perry JD, Sandoe JA. Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother. 2004 Dec. 54(6):971-81. [QxMD MEDLINE Link].
Horstkotte D, Follath F, Gutschik E, Lengyel M, Oto A, Pavie A, et al. Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology. Eur Heart J. 2004 Feb. 25(3):267-76. [QxMD MEDLINE Link].
Le Quellec A, Bessis D, Perez C, Ciurana AJ. Endocarditis due to beta-lactamase-producing Cardiobacterium hominis. Clin Infect Dis. Nov 1994. 19(5):994-5. [QxMD MEDLINE Link].
Nerard JL, Snydman DR. Miscellaneous gram-negative bacilli: Acinetobacter, Cardiobacterium, Actinobacillus, Chromobacterium, Capnocytophaga, and others. Gorbach SL, Bartlett JG, Blacklow NR. Infectious Diseases. Philadelphia, Pa: WB Saunders; 1992. 1543-55.
Nurnberger M, Treadwell T, Lin B, Weintraub A. Pacemaker lead infection and vertebral osteomyelitis presumed due to Cardiobacterium hominis. Clin Infect Dis. 1998 Oct. 27(4):890-1. [QxMD MEDLINE Link].
Silver SE. Ruptured mycotic aneurysm of the superior mesenteric artery that was due to cardiobacterium endocarditis. Clin Infect Dis. Dec 1999. 29(6):1573-4. [QxMD MEDLINE Link].
Wilson WR, Karchmer AW, Dajani AS, Taubert KA, Bayer A, Kaye D, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA. 1995 Dec 6. 274(21):1706-13. [QxMD MEDLINE Link].

Media Gallery

of 0

Author

Kerry O Cleveland, MD Professor of Medicine, University of Tennessee College of Medicine; Consulting Staff, Department of Internal Medicine, Division of Infectious Diseases, Methodist Healthcare of Memphis

Kerry O Cleveland, MD is a member of the following medical societies: American College of Physicians, Infectious Diseases Society of America, Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Coauthor(s)

Pierre A Dorsainvil, MD Medical Director, HIV Specialist, Palm Beach County Main Detention Center; Consulting Staff, Department of Internal Medicine, Division of Infectious Diseases, Lake Ida Medical Center

Disclosure: Nothing to disclose.

Michael Gelfand, MD, FACP Chief, Professor, Department of Internal Medicine, Division of Infectious Diseases, Methodist Healthcare of Memphis, University of Tennessee Health Science Center College of Medicine

Michael Gelfand, MD, FACP is a member of the following medical societies: American College of Physicians, American Medical Association, American Society for Microbiology, Infectious Diseases Society of America, Southern Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Joseph F John, Jr, MD, FACP, FIDSA, FSHEA Clinical Professor of Medicine, Molecular Genetics and Microbiology, Medical University of South Carolina College of Medicine; Associate Chief of Staff for Education, Ralph H Johnson Veterans Affairs Medical Center

Joseph F John, Jr, MD, FACP, FIDSA, FSHEA is a member of the following medical societies: Charleston County Medical Association, Infectious Diseases Society of America, South Carolina Infectious Diseases Society

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Medical Association, Association of Professors of Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Additional Contributors

Thomas E Herchline, MD Professor of Medicine, Wright State University, Boonshoft School of Medicine; Medical Consultant, Public Health, Dayton and Montgomery County (Ohio) Tuberculosis Clinic

Thomas E Herchline, MD is a member of the following medical societies: Alpha Omega Alpha, Infectious Diseases Society of America, Infectious Diseases Society of Ohio

Disclosure: Received research grant from: Regeneron.

Burke A Cunha, MD Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Sections Cardiobacterium
Overview
Presentation
- History
- Physical
- Causes
- Complications
- Show All
DDx
Workup
Treatment
Medication
References

Cardiobacterium Treatment & Management

Medical Care

Prevention

Further Outpatient Care

Further Inpatient Care

References

Tables

Contributor Information and Disclosures

What would you like to print?